SHANGHAI PHARMACEUTICALS HOLDING CO LTD financial statements, including revenue, expenses, profit, and loss
The total revenue of S1R for the last quarter is 8.80 B EUR, and it's 1.24% lower compared to the previous quarter. The net income of Q3 24 is 139.80 M EUR.